Monogenic neurological disorders of sphingolipid metabolism.

F. Sabourdy,L. Astudillo,C. Colacios,Patricia Dubot,Marguerite Mrad,B. Ségui,N. Andrieu-Abadie,T. Levade

DOI: https://doi.org/10.1016/j.bbalip.2015.01.010

2015-08-01

Biochimica et Biophysica Acta

Abstract:

What problem does this paper attempt to address?

Human genetic defects of sphingolipid synthesis

Patricia Dubot,Frédérique Sabourdy,Thierry Levade

DOI: https://doi.org/10.1002/jimd.12745

IF: 4.7501

2024-05-07

Journal of Inherited Metabolic Disease

Abstract:Sphingolipids are ubiquitous lipids, present in the membranes of all cell types, the stratum corneum and the circulating lipoproteins. Autosomal recessive as well as dominant diseases due to disturbed sphingolipid biosynthesis have been identified, including defects in the synthesis of ceramides, sphingomyelins and glycosphingolipids. In many instances, these gene variants result in the loss of catalytic function of the mutated enzymes. Additional gene defects implicate the subcellular localization of the sphingolipid‐synthesizing enzyme, the regulation of its activity, or even the function of a sphingolipid‐transporter protein. The resulting metabolic alterations lead to two major, non‐exclusive types of clinical manifestations: a neurological disease, more or less rapidly progressive, associated or not with intellectual disability, and an ichthyotic‐type skin disorder. These phenotypes highlight the critical importance of sphingolipids in brain and skin development and homeostasis. The present article reviews the clinical symptoms, genetic and biochemical alterations, pathophysiological mechanisms and therapeutic options of this relatively novel group of metabolic diseases.

genetics & heredity,endocrinology & metabolism,medicine, research & experimental
Rare Diseases in Glycosphingolipid Metabolism

Hongwen Zhou,Zhoulu Wu,Yiwen Wang,Qinyi Wu,Moran Hu,Shuai Ma,Min Zhou,Yan Sun,Baowen Yu,Jingya Ye,Wanzi Jiang,Zhenzhen Fu,Yingyun Gong

DOI: https://doi.org/10.1007/978-981-19-0394-6_13

2022-01-01

Advances in experimental medicine and biology

Abstract:Sphingolipidoses is a cluster of genetic rare disorders regarding glycosphingolipid metabolism, classified as lysosomal storage disorders (LSD). Here, we focus on eight inheritable diseases, including GM1 gangliosidosis, GM2 gangliosidosis, Fabry disease, Gaucher's disease, metachromatic leukodystrophy, Krabbe disease, Niemann-Pick disease A and B, and Farber disease. Mostly, pathogenic mutations in the key enzyme are loss-function, resulting in accumulation of substrates and deficiency of products. Thus, cellular overload of substrates causes lipotoxicity, which is deleterious to cellular and organ function. In the terms of clinical manifestations in sphingolipidoses, multiple systems and organs, especially central nervous system (CNS) are usually affected. As for diagnosis strategy, enzymatic activity assay and genetic sequencing are helpful. Up till now, limited treatment approaches have approved for treating sphingolipidoses, with some potential strategies for further evaluation. In general, enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and molecular chaperones are feasible choices for enzyme deficiency disorders, but these therapies are limited to relieve CNS lesions and symptoms due to prevention from blood-brain barrier. Other possible treatments such as gene therapy, bone marrow transplantation (BMT), and hematopoietic stem cell transplantation (HSCT) need further evaluation.
The Pathology of Primary Familial Brain Calcification: Implications for Treatment

Xuan Xu,Hao Sun,Junyu Luo,Xuewen Cheng,Wenqi Lv,Wei Luo,Wan‐Jin Chen,Zhi‐Qi Xiong,Jing-Yu Liu

DOI: https://doi.org/10.1007/s12264-022-00980-0

2022-01-01

Abstract:Primary familial brain calcification (PFBC) is an inherited neurodegenerative disorder mainly characterized by progressive calcium deposition bilaterally in the brain, accompanied by various symptoms, such as dystonia, ataxia, parkinsonism, dementia, depression, headaches, and epilepsy. Currently, the etiology of PFBC is largely unknown, and no specific prevention or treatment is available. During the past 10 years, six causative genes (SLC20A2, PDGFRB, PDGFB, XPR1, MYORG, and JAM2) have been identified in PFBC. In this review, considering mechanistic studies of these genes at the cellular level and in animals, we summarize the pathogenesis and potential preventive and therapeutic strategies for PFBC patients. Our systematic analysis suggests a classification for PFBC genetic etiology based on several characteristics, provides a summary of the known composition of brain calcification, and identifies some potential therapeutic targets for PFBC.
Mysterious sphingolipids: metabolic interrelationships at the center of pathophysiology

Rama Jamjoum,Saurav Majumder,Batoul Issleny,Johnny Stiban

DOI: https://doi.org/10.3389/fphys.2023.1229108

IF: 4

2024-01-03

Frontiers in Physiology

Abstract:Metabolic pathways are complex and intertwined. Deficiencies in one or more enzymes in a given pathway are directly linked with genetic diseases, most of them having devastating manifestations. The metabolic pathways undertaken by sphingolipids are diverse and elaborate with ceramide species serving as the hubs of sphingolipid intermediary metabolism and function. Sphingolipids are bioactive lipids that serve a multitude of cellular functions. Being pleiotropic in function, deficiency or overproduction of certain sphingolipids is associated with many genetic and chronic diseases. In this up-to-date review article, we strive to gather recent scientific evidence about sphingolipid metabolism, its enzymes, and regulation. We shed light on the importance of sphingolipid metabolism in a variety of genetic diseases and in nervous and immune system ailments. This is a comprehensive review of the state of the field of sphingolipid biochemistry.

physiology
Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis

Payam Mohassel,Sandra Donkervoort,Museer A. Lone,Matthew Nalls,Kenneth Gable,Sita D. Gupta,A. Reghan Foley,Ying Hu,Jonas Alex Morales Saute,Ana Lucila Moreira,Fernando Kok,Alessandro Introna,Giancarlo Logroscino,Christopher Grunseich,Alec R. Nickolls,Naemeh Pourshafie,Sarah B. Neuhaus,Dimah Saade,Andrea Gangfuß,Heike Kölbel,Zoe Piccus,Claire E. Le Pichon,Chiara Fiorillo,Cindy V. Ly,Ana Töpf,Lauren Brady,Sabine Specht,Aliza Zidell,Helio Pedro,Eric Mittelmann,Florian P. Thomas,Katherine R. Chao,Chamindra G. Konersman,Megan T. Cho,Tracy Brandt,Volker Straub,Anne M. Connolly,Ulrike Schara,Andreas Roos,Mark Tarnopolsky,Ahmet Höke,Robert H. Brown,Chia-Hsueh Lee,Thorsten Hornemann,Teresa M. Dunn,Carsten G. Bönnemann

DOI: https://doi.org/10.1038/s41591-021-01346-1

IF: 82.9

2021-05-31

Nature Medicine

Abstract:Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease of the lower and upper motor neurons with sporadic or hereditary occurrence. Age of onset, pattern of motor neuron degeneration and disease progression vary widely among individuals with ALS. Various cellular processes may drive ALS pathomechanisms, but a monogenic direct metabolic disturbance has not been causally linked to ALS. Here we show SPTLC1 variants that result in unrestrained sphingoid base synthesis cause a monogenic form of ALS. We identified four specific, dominantly acting SPTLC1 variants in seven families manifesting as childhood-onset ALS. These variants disrupt the normal homeostatic regulation of serine palmitoyltransferase (SPT) by ORMDL proteins, resulting in unregulated SPT activity and elevated levels of canonical SPT products. Notably, this is in contrast with SPTLC1 variants that shift SPT amino acid usage from serine to alanine, result in elevated levels of deoxysphingolipids and manifest with the alternate phenotype of hereditary sensory and autonomic neuropathy. We custom designed small interfering RNAs that selectively target the SPTLC1 ALS allele for degradation, leave the normal allele intact and normalize sphingolipid levels in vitro. The role of primary metabolic disturbances in ALS has been elusive; this study defines excess sphingolipid biosynthesis as a fundamental metabolic mechanism for motor neuron disease.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Sphingolipids: membrane microdomains in brain development, function and neurological diseases

Anne S. B. Olsen,Nils J. Færgeman

DOI: https://doi.org/10.1098/rsob.170069

2017-05-01

Open Biology

Abstract:Sphingolipids are highly enriched in the nervous system where they are pivotal constituents of the plasma membranes and are important for proper brain development and functions. Sphingolipids are not merely structural elements, but are also recognized as regulators of cellular events by their ability to form microdomains in the plasma membrane. The significance of such compartmentalization spans broadly from being involved in differentiation of neurons and synaptic transmission to neuronal–glial interactions and myelin stability. Thus, perturbations of the sphingolipid metabolism can lead to rearrangements in the plasma membrane, which has been linked to the development of various neurological diseases. Studying microdomains and their functions has for a long time been synonymous with studying the role of cholesterol. However, it is becoming increasingly clear that microdomains are very heterogeneous, which among others can be ascribed to the vast number of sphingolipids. In this review, we discuss the importance of microdomains with emphasis on sphingolipids in brain development and function as well as how disruption of the sphingolipid metabolism (and hence microdomains) contributes to the pathogenesis of several neurological diseases.

biochemistry & molecular biology
Compound Heterozygous Mutations in the Neuraminidase 1 Gene in Type 1 Sialidosis: A Case Report and Review of Literature

Lan-Xiao Cao,Ying Liu,Zhao-Jun Song,Bao-Rong Zhang,Wen-Ying Long,Guo-Hua Zhao

DOI: https://doi.org/10.12998/wjcc.v9.i3.623

2021-01-01

World Journal of Clinical Cases

Abstract:BACKGROUND Type 1 sialidosis, also known as cherry-red spot-myoclonus syndrome, is a rare autosomal recessive lysosomal storage disorder presenting in the second decade of life. The most common symptoms are myoclonus, ataxia and seizure. It is rarely encountered in the Chinese mainland. CASE SUMMARY A 22-year-old male presented with complaints of progressive myoclonus, ataxia and slurred speech, without visual symptoms; the presenting symptoms began at the age of 15-year-old. Whole exome sequencing revealed two pathogenic heterozygous missense variants [c.239C>T (p.P80L) and c.544A>G (p.S182G) in the neuraminidase 1 (NEU1) gene], both of which have been identified previously in Asian patients with type 1 sialidosis. All three patients identified in Mainland China come from three unrelated families, but all three show the NEU1 mutations p.S182G and p.P80L pathogenic variants. Increasing sialidase activity through chaperones is a promising therapeutic target in sialidosis. CONCLUSION Through retrospective analysis and summarizing the clinical and genetic characteristics of type 1 sialidosis, we hope to raise awareness of lysosomal storage disorders among clinicians and minimize the delay in diagnosis.
A Genetic Model of Substrate Deprivation Therapy for a Glycosphingolipid Storage Disorder.

YJ Liu,R Wada,H Kawai,K Sango,CX Deng,T Tai,MP McDonald,K Araujo,JN Crawley,U Bierfreund,K Sandhoff,K Suzuki,RL Proia

DOI: https://doi.org/10.1172/jci5542

1999-01-01

Abstract:Inherited defects in the degradation of glycosphingolipids (GSLs) cause a group of severe diseases known as GSL storage disorders. There are currently no effective treatments for the majority of these disorders. We have explored a new treatment paradigm, substrate deprivation therapy, by constructing a genetic model in mice. Sandhoff's disease mice, which abnormally accumulate GSLs, were bred with mice that were blocked in their synthesis of GSLs. The mice with simultaneous defects in GSL synthesis and degradation no longer accumulated GSLs, had improved neurologic function, and had a much longer life span. However, these mice eventually developed a late-onset neurologic disease because of accumulation of another class of substrate, oligosaccharides. The results support the validity of the substrate deprivation therapy and also highlight some limitations.
Functional and Molecular Characterization of New SPTLC1 Missense Variants in Patients with Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1)

Julie Rochat,André Blavier,Séverine Ruet,Sophie Vasseur,Angela Puma,Béatrice Desnous,Victor Chan,Emilien Delmont,Shahram Attarian,Raul Juntas Morales,Isabelle Quadrio,Léo Vidoni,Nathalie Bonello-Palot,David Cheillan

DOI: https://doi.org/10.3390/genes15060692

IF: 4.141

2024-05-27

Genes

Abstract:Hereditary sensory and autonomic neuropathy type 1 is an autosomal dominant neuropathy caused by the SPTLC1 or SPTLC2 variants. These variants modify the preferred substrate of serine palmitoyl transferase, responsible for the first step of de novo sphingolipids synthesis, leading to accumulation of cytotoxic deoxysphingolipids. Diagnosis of HSAN1 is based on clinical symptoms, mainly progressive loss of distal sensory keep, and genetic analysis. Aim: Identifying new SPTLC1 or SPTLC2 "gain-of-function" variants raises the question as to their pathogenicity. This work focused on characterizing six new SPTLC1 variants using in silico prediction tools, new meta-scores, 3D modeling, and functional testing to establish their pathogenicity. Methods: Variants from six patients with HSAN1 were studied. In silico, CADD and REVEL scores and the 3D modeling software MITZLI were used to characterize the pathogenic effect of the variants. Functional tests based on plasma sphingolipids quantification (total deoxysphinganine, ceramides, and dihydroceramides) were performed by tandem mass spectrometry. Results: In silico predictors did not provide very contrasting results when functional tests discriminated the different variants according to their impact on deoxysphinganine level or canonical sphingolipids synthesis. Two SPTLC1 variants were newly described as pathogenic: SPTLC1 NM_006415.4:c.998A>G and NM_006415.4:c.1015G>A. Discussion: The combination of the different tools provides arguments to establish the pathogenicity of these new variants. When available, functional testing remains the best option to establish the in vivo impact of a variant. Moreover, the comprehension of metabolic dysregulation offers opportunities to develop new therapeutic strategies for these genetic disorders.

genetics & heredity
Plasma Membrane Remodelling in GM2 Gangliosidoses Drives Synaptic Dysfunction

Alex S Nicholson,David A Priestman,Robin Antrobus,James C. Williamson,Reuben Bush,Henry G Barrow,Emily Smith,Kostantin Dobrenis,Nicholas A Bright,Frances M. Platt,Janet E Deane

DOI: https://doi.org/10.1101/2024.08.20.608810

2024-10-01

Abstract:Glycosphingolipids (GSL) are important bioactive components of cellular membranes. Complex GSLs, containing sialic acid residues are known as gangliosides and are highly abundant in the brain. Diseases of ganglioside metabolism often result in severe, early-onset neurodegeneration. The ganglioside GM2 is the substrate of the hydrolytic lysosomal β-hexosaminidase A (HexA) enzyme and when subunits of this enzyme are non-functional, GM2 lipid accumulates in cells leading to the GM2 gangliosidoses, Tay-Sachs and Sandhoff diseases. We have developed high-quality i3Neuron-based models of Tay-Sachs and Sandhoff diseases, that demonstrate storage of GM2, formation of membrane whorls and accumulation of endolysosomal proteins consistent with disease phenotypes. Importantly, in addition to lysosomal dysfunction, the composition of the plasma membrane (PM) is significantly impacted in these diseases with changes in the abundance of both lipids and proteins. The changes to the PM proteome are driven in part by exocytosis of lysosomal material resulting in the aberrant accumulation of lysosomal proteins and lipids on the cell surface. The altered abundance of GM2 at the PM was striking, bringing the abundance of this precursor lipid up to that of the common neuronal gangliosides. Furthermore, the PM profiling identifies significant changes in synaptic protein abundances with direct functional impact on neuronal activity including rapid electrical firing consistent with neuronal hyperactivity. This work provides mechanistic insights into neuronal dysfunction in the GM2 gangliosidoses and highlights that these are also severe PM disorders. This work has broad implications for other lysosomal storage disorders and late-onset neurodegenerative diseases involving sphingolipid dysregulation.

Neuroscience
The role of Sphingolipids in myelination and myelin stability and their involvement in childhood and adult demyelinating disorders

Paola Giussani,Alessandro Prinetti,Cristina Tringali

DOI: https://doi.org/10.1111/jnc.15133

2020-08-25

Journal of Neurochemistry

Abstract:Multiple sclerosis (MS) represents the most common demyelinating disease affecting the central nervous system (CNS) in adults as well as in children. Furthermore, in children, in addition to acquired diseases such as MS, genetically inherited diseases significantly contribute to the incidence of demyelinating disorders. Some genetic defects lead to sphingolipid alterations that are able to elicit neurological symptoms. Sphingolipids are essential for brain development, and their aberrant functionality may thus contribute to demyelinating diseases such as MS. In particular, sphingolipidoses caused by deficits of sphingolipid‐metabolizing enzymes, are often associated with demyelination. Sphingolipids are not only structural molecules but also bioactive molecules involved in the regulation of cellular events such as development of the nervous system, myelination, and maintenance of myelin stability. Changes in the sphingolipid metabolism deeply affect plasma membrane organization. Thus, changes in myelin sphingolipid composition might crucially contribute to the phenotype of diseases characterized by demyelinalization. Several sphingolipids such as ceramide/dihydroceramide, sphingosine/dihydrosphingosine, glucosylceramide and, galactosylceramide act in myelin formation during rat brain development and in human brain demyelination during the pathogenesis of MS, suggesting that this knowledge could be useful to identify targets for possible therapies.

biochemistry & molecular biology,neurosciences
Endo-lysosomal dysfunction and neuronal–glial crosstalk in Niemann–Pick type C disease

Mariagiovanna Malara,Matthias Prestel,Sabina Tahirovic

DOI: https://doi.org/10.1098/rstb.2022.0388

2024-02-19

Philosophical Transactions of the Royal Society B Biological Sciences

Abstract:Niemann–Pick type C (NPC) disease is a rare progressive lysosomal lipid storage disorder that manifests with a heterogeneous spectrum of clinical syndromes, including visceral, neurological and psychiatric symptoms. This monogenetic autosomal recessive disease is largely caused by mutations in the NPC1 gene, which controls intracellular lipid homeostasis. Vesicle-mediated endo-lysosomal lipid trafficking and non-vesicular lipid exchange via inter-organelle membrane contact sites are both regulated by the NPC1 protein. Loss of NPC1 function therefore triggers intracellular accumulation of diverse lipid species, including cholesterol, glycosphingolipids, sphingomyelin and sphingosine. The NPC1-mediated dysfunction of lipid transport has severe consequences for all brain cells, leading to neurodegeneration. Besides the cell-autonomous contribution of neuronal NPC1, aberrant NPC1 signalling in other brain cells is critical for the pathology. We discuss here the importance of endo-lysosomal dysfunction and a tight crosstalk between neurons, oligodendrocytes, astrocytes and microglia in NPC pathology. We strongly believe that a cell-specific rescue may not be sufficient to counteract the severity of the NPC pathology, but targeting common mechanisms, such as endo-lysosomal and lipid trafficking dysfunction, may ameliorate NPC pathology. This article is part of a discussion meeting issue ‘Understanding the endo-lysosomal network in neurodegeneration’.

biology
The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases

Sidharth Sankar Kar,Soumya Ranjan Gharai,Sujit Kumar Sahu,V. Ravichandiran,Sharada Prasanna Swain

DOI: https://doi.org/10.2174/0115680266288509240422112839

2024-04-26

Current Topics in Medicinal Chemistry

Abstract:Abstract: Sphingosine 1-phosphate (S1P) is extensively researched as a lysophospholipid and is crucial in various physiological and pathological processes. It achieves this via signalling through five different subtypes of G protein-coupled receptors (GPCRs), namely S1PR1 to S1PR5. S1PR modulators possess the ability to traverse the blood-brain barrier, potentially leading to direct ac-tions within the Central Nervous System (CNS). S1PR modulators specifically bind to receptors located on the surface of naive and central memory lymphocytes, causing these cells to be trapped or confined within the lymph node. The investigation of the S1P pathway has resulted in the ap-proval of three S1PR modulators, namely fingolimod, siponimod, and ozanimod, as medications for the treatment of patients suffering from Multiple Sclerosis (MS). Additionally, new S1PR modulators, such as ponesimod and etrasimod, are currently being developed and tested in clini-cal trials. Research on the creation of S1P modulators in neurodegenerative illnesses is ongoing as scientists continue to explore novel possibilities for selective S1P modulators. This study provides a concise overview of sphingolipid metabolism, the mechanism by which S1P receptors are af-fected, and the structural characteristics of several small molecule S1P modulators, with a particu-lar focus on their structure-activity connections.

chemistry, medicinal
Gaucher Disease: A Glance from a Medicinal Chemistry Perspective

Filippo Prencipe,Chiara Barzan,Chiara Savian,Giampiero Spalluto,Emanuele Carosati,Marco De Amici,Giorgio Mosconi,Teresa Gianferrara,Stephanie Federico,Tatiana Da Ros

DOI: https://doi.org/10.1002/cmdc.202300641

IF: 3.54

2024-02-09

ChemMedChem

Abstract:Rare diseases are particular pathological conditions affecting a limited number of people and few drugs are known to be effective as therapeutic treatment. Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase, belongs to this class of disorders, and it is considered the most common among the Lysosomal Storage Diseases. The two main therapeutic approaches are the Enzyme Replacement Therapy (ERT) and the Substrate Reduction Therapy (SRT). ERT, consisting in replacing the defective enzyme by administering a recombinant enzyme, is effective in alleviating the visceral symptoms, hallmarks of the most common subtype of the disease whereas it has no effects when symptoms involve CNS, since the recombinant protein is unable to significantly cross the Blood Brain Barrier. The SRT strategy involves inhibiting glucosylceramide synthase (GCS), the enzyme responsible for the production of the associated storage molecule. The rational design of new inhibitors of GCS has been hampered by the lack of either the crystal structure of the enzyme or an in‐silico model of the active site which could provide important information regarding the interactions of potential inhibitors with the target, but, despite this, interesting results have been obtained and are herein reviewed.

pharmacology & pharmacy,chemistry, medicinal
Expanding the genetic spectrum of primary familial brain calcification due to SLC2OA2 mutations: a case series

Luca Magistrelli,Roberta Croce,Fabiola De Marchi,Chiara Basagni,Miryam Carecchio,Nicola Nasuelli,Roberto Cantello,Federica Invernizzi,Barbara Garavaglia,Cristoforo Comi,Letizia Mazzini,Sandra D'Alfonso,Lucia Corrado

DOI: https://doi.org/10.1007/s10048-021-00634-9

Neurogenetics

Abstract:Primary familial brain calcification (PFBC) is a neurological condition characterized by the presence of intracranial calcifications, mainly involving basal ganglia, thalamus, and dentate nuclei. So far, six genes have been linked to this condition: SLC20A2, PDGFRB, PDGFB, and XPR1 inherited as autosomal-dominant trait, while MYORG and JAM2 present a recessive pattern of inheritance. Patients mainly present with movement disorders, psychiatric disturbances, and cognitive decline or are completely asymptomatic and calcifications may represent an occasional finding. Here we present three variants in SLC20A2, two exonic and one intronic, which we found in patients with PFBC associated to three different clinical phenotypes. One variant is novel and two were already described as variants of uncertain significance. We confirm the pathogenicity of these three variants and suggest a broadening of the phenotypic spectrum associated with mutations in SLC20A2.
Recurrent "outsider" intronic variation in the SLC5A6 gene causes severe mixed axonal and demyelinating neuropathy, cyclic vomiting and optic atrophy in 3 families from Maghreb

Lamisse Mansour-Hendili,Cyril Gitiaux,Madeleine Harion,Céline Latouche,Bénédicte Heron,Tanya Stojkovic,Mélanie Rama,Thomas Smol,Anne Sophie Jourdain,Karine Mention,Yann Nadjar,Manuel Schiff,Julie Lemale,Jamal Ghoumid,Frédéric Gottrand,Cécile Talbotec,Agnès Rötig,Benoît Funalot,Isabelle Desguerre

DOI: https://doi.org/10.3389/fgene.2024.1352006

IF: 3.7

2024-01-30

Frontiers in Genetics

Abstract:Sodium dependent multivitamin transporter (SMVT) deficiency is a very rare autosomal recessive disorder characterized by multisystemic clinical manifestations due to combined biotin, panthotenic acid and lipoic acid deficiency. About 10 families have been described so far. Accurate diagnosis is crucial because of the possibility of a supplementation treatment with proven efficacy. Here we describe 4 new patients (3 additional families) originating from the same world region (Algeria, Maghreb). All patients, born form consanguineous parents, were homozygous carriers of the same intronic variation, outside of canonical sites, in the SLC5A6 gene encoding SMVT. RNA study in one family allowed confirming the pathogenic effect of the variation and re-classifying this variant of uncertain significance as pathogenic, opening the possibility of genetic counseling and treatment. The identification of the same variation in three distinct and apparently unrelated families is suggestive of a founder effect. The phenotype of all patients was very similar, with systematic optic atrophy (initially considered as a very rare sign), severe cyclic vomiting, and rapidly progressive mixed axonal and demyelinating sensory motor neuropathy.

genetics & heredity
Two compound heterozygous variants in the CLN8 gene are responsible for neuronal cereidolipofuscinoses disorder in a child: a case report

Federico Baltar,Camila Simoes,Francisco Garagorry,Martín Graña,Soledad Rodríguez,María Haydée Aunchayna,Alejandra Tapié,Alfredo Cerisola,Gabriel González,Hugo Naya,Lucía Spangenberg,Víctor Raggio

DOI: https://doi.org/10.3389/fped.2024.1379254

IF: 3.569

2024-05-02

Frontiers in Pediatrics

Abstract:Background: Neuronal Ceroid Lipofuscinosis (NCL) disorders, recognized as the primary cause of childhood dementia globally, constitute a spectrum of genetic abnormalities. CLN8, a subtype within NCL, is characterized by cognitive decline, motor impairment, and visual deterioration. This study focuses on an atypical case with congenital onset and a remarkably slow disease progression. Methods: Whole-genome sequencing at 30× coverage was employed as part of a national genomics program to investigate the genetic underpinnings of rare diseases. This genomic approach aimed to challenge established classifications (vLINCL and EPMR) and explore the presence of a continuous phenotypic spectrum associated with CLN8 . Results: The whole-genome sequencing revealed two novel likely pathogenic mutations in the CLN8 gene on chromosome 8p23.3. These mutations were not previously associated with CLN8-related NCL. Contrary to established classifications (vLINCL and EPMR), our findings suggest a continuous phenotypic spectrum associated with CLN8. Pathological subcellular markers further validated the genomic insights. Discussion: The identification of two previously undescribed likely pathogenic CLN8 gene mutations challenges traditional classifications and highlights a more nuanced phenotypic spectrum associated with CLN8. Our findings underscore the significance of genetic modifiers and interactions with unrelated genes in shaping variable phenotypic outcomes. The inclusion of pathological subcellular markers further strengthens the validity of our genomic insights. This research enhances our understanding of CLN8 disorders, emphasizing the need for comprehensive genomic analyses to elucidate the complexity of phenotypic presentations and guide tailored therapeutic strategies. The identification of new likely pathogenic mutations underscores the dynamic nature of CLN8 -related NCL and the importance of individualized approaches to patient management.

pediatrics
Sphingolipid metabolism in brain insulin resistance and neurological diseases

Meng Mei,Maochang Liu,Yan Mei,Jing Zhao,Yang Li

DOI: https://doi.org/10.3389/fendo.2023.1243132

IF: 6.055

2023-10-07

Frontiers in Endocrinology

Abstract:Sphingolipids, as members of the large lipid family, are important components of plasma membrane. Sphingolipids participate in biological signal transduction to regulate various important physiological processes such as cell growth, apoptosis, senescence, and differentiation. Numerous studies have demonstrated that sphingolipids are strongly associated with glucose metabolism and insulin resistance. Insulin resistance, including peripheral insulin resistance and brain insulin resistance, is closely related to the occurrence and development of many metabolic diseases. In addition to metabolic diseases, like type 2 diabetes, brain insulin resistance is also involved in the progression of neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. However, the specific mechanism of sphingolipids in brain insulin resistance has not been systematically summarized. This article reviews the involvement of sphingolipids in brain insulin resistance, highlighting the role and molecular biological mechanism of sphingolipid metabolism in cognitive dysfunctions and neuropathological abnormalities of the brain.

endocrinology & metabolism
Characteristics and hormonal control of some glycoprotein glycosyl-transferase reactions in male reproductive organs.

B. Tadolini,T. Wilson,P. Reddy,H. G. Williams-Ashman

DOI: https://doi.org/10.1016/0065-2571(77)90023-1

Advances in Enzyme Regulation

Abstract:
Penetrance, variable expressivity and monogenic neurodevelopmental disorders

Servane de Masfrand,Benjamin Cogné,Mathilde Nizon,Wallid Deb,Alice Goldenberg,François Lecoquierre,Gaël Nicolas,Marie Bournez,Antonio Vitobello,Frédéric Tran Mau-Them,Gwenaël le Guyader,Frédéric Bilan,Peter Bauer,Christiane Zweier,Juliette Piard,Laurent Pasquier,Stéphane Bézieau,Bénédicte Gerard,Laurence Faivre,Pascale Saugier-Veber,Amélie Piton,Bertrand Isidor

DOI: https://doi.org/10.1016/j.ejmg.2024.104932

IF: 2.465

2024-03-07

European Journal of Medical Genetics

Abstract:Purpose Incomplete penetrance is observed for most monogenic diseases. However, for neurodevelopmental disorders, the interpretation of single and multi-nucleotide variants (SNV/MNVs) is usually based on the paradigm of complete penetrance. Method From 2020 to 2022, we proposed a collaboration study with the French molecular diagnosis for intellectual disability network. The aim was to recruit families for whom the index case, diagnosed with a neurodevelopmental disorder, was carrying a pathogenic or likely pathogenic variant for an OMIM morbid gene and inherited from an asymptomatic parent. Grandparents were analyzed when available for segregation study. Results We identified 12 patients affected by a monogenic neurodevelopmental disorder caused by likely pathogenic or pathogenic variant (SNV/MNV) inherited from an asymptomatic parent. These genes were usually associated with de novo variants. The patients carried different variants (1 splice-site variant, 4 nonsense and 7 frameshift) in 11 genes: CAMTA1, MBD5, KMT2C, KMT2E, ZMIZ1, MN1, NDUFB11, CUL3, MED13, ARID2 and RERE . Grandparents have been tested in 6 families, and each time the variant was confirmed de novo in the healthy carrier parent. Conclusion Incomplete penetrance for SNV and MNV in neurodevelopmental disorders might be more frequent than previously thought. This point is crucial to consider for interpretation of variants, family investigation, genetic counseling, and prenatal diagnosis. Molecular mechanisms underlying this incomplete penetrance still need to be identified.

genetics & heredity

Monogenic neurological disorders of sphingolipid metabolism.

Human genetic defects of sphingolipid synthesis

Rare Diseases in Glycosphingolipid Metabolism

The Pathology of Primary Familial Brain Calcification: Implications for Treatment

Mysterious sphingolipids: metabolic interrelationships at the center of pathophysiology

Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis

Sphingolipids: membrane microdomains in brain development, function and neurological diseases

Compound Heterozygous Mutations in the Neuraminidase 1 Gene in Type 1 Sialidosis: A Case Report and Review of Literature

A Genetic Model of Substrate Deprivation Therapy for a Glycosphingolipid Storage Disorder.

Functional and Molecular Characterization of New SPTLC1 Missense Variants in Patients with Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1)

Plasma Membrane Remodelling in GM2 Gangliosidoses Drives Synaptic Dysfunction

The role of Sphingolipids in myelination and myelin stability and their involvement in childhood and adult demyelinating disorders

Endo-lysosomal dysfunction and neuronal–glial crosstalk in Niemann–Pick type C disease

The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases

Gaucher Disease: A Glance from a Medicinal Chemistry Perspective

Expanding the genetic spectrum of primary familial brain calcification due to SLC2OA2 mutations: a case series

Recurrent "outsider" intronic variation in the SLC5A6 gene causes severe mixed axonal and demyelinating neuropathy, cyclic vomiting and optic atrophy in 3 families from Maghreb

Two compound heterozygous variants in the CLN8 gene are responsible for neuronal cereidolipofuscinoses disorder in a child: a case report

Sphingolipid metabolism in brain insulin resistance and neurological diseases

Characteristics and hormonal control of some glycoprotein glycosyl-transferase reactions in male reproductive organs.

Penetrance, variable expressivity and monogenic neurodevelopmental disorders